<DOC>
	<DOCNO>NCT02842541</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity , pharmacokinetics 3 dose level EBI-031 give intravitreal injection subject diabetic macular edema . There two arm study , single dose arm ( 1 dose ) repeat dose arm ( 1 dose month 3 month ) . Eligible subject initially enroll single dose arm 3 6 subject dose 3 dose level . Safety assess 28 day single dose prior move next high dose level . Once subject single dose arm dose EBI-031 safety assess eligible subject begin enrol repeat dose arm . Subjects repeat dose arm receive one dose month 3 month assess safety . Escalation next high dose occur determine safe proceed next dose level . Six subject dose 3 dose level .</brief_summary>
	<brief_title>Safety Study Intravitreal EBI-031 Given Single Repeat Injection Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Give write voluntary informed consent authorization require local law Have diagnosis Type 1 2 diabetes mellitus Have decrease vision determine primarily result DME study eye Mean central foveal thickness Spectral Domain Ocular Coherence Tomography ( SDOCT ) &gt; 325 study eye within 2 week dose Have best correct Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter score &lt; 73 ( ~20/40 ) &gt; 19 ( ~20/400 ) study eye within 2 week dose . Female pregnant lactate Any prior history antiinterleukin 6 ( antiIL6 ) treatment , example : tocilizumab , sirukumab , sarilumab , olokizumab Any concurrent biologics immune disease antitumor necrosis factor ( TNF ) : Enbrel ( etanercept ) , Humira ( adalimumab ) , Remicade ( infliximab ) ; antiinterleukin 12 ( antiIL12 ) : Stelara ( ustekinumab ) ; antiinterleukin 1 ( antiIL1 ) : Kineret ( anakinra ) , Ilaris ( canakinumab ) , Arcalyst ( rilonacept ) . Unstable , uncontrolled diabetes define hemoglobin A1C ( HbA1C ) â‰¥10.5 % within 3 month prior dose EBI031 Received intravitreal antivascular endothelial growth factor ( antiVEGF ) Eylea ( aflibercept ) within 8 week , Lucentis ( ranibizumab ) Avastin ( bevacizumab ) within 4 month prior EBI031 Significant renal disease , liver disease , acute congestive heart failure History myocardial infarction ( MI ) , stroke , transient ischemic attack ( TIA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>